Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06269510 · ClinicalTrials.gov registry record · NA

Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients

A NA study of Liver Diseases and Alcohol-related Liver Disease, sponsored by Henry Ford Health System.

Recruiting
Registry status
NA
Development phase
268
Enrollment target
1
Study location

NCT06269510 is a NA study of Liver Diseases and Alcohol-related Liver Disease that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 268 participants, below the 61,150-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06269510, a NA study of Liver Diseases and Alcohol-related Liver Disease, is actively recruiting participants, sponsored by Henry Ford Health System.

RECRUITING
Registry status
NA
Development phase
268 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.

Interventions

  • BEHAVIORAL Enhanced Usual Care
  • BEHAVIORAL ENGAGE-ALD Application (APP)
  • BEHAVIORAL Treatment Facilitation bundle

Study Locations (1)

Michigan

  • Henry Ford Health - Detroit

Trial Details

FieldValue
Enrollment Target 268 participants
Start Date 2026-01-28
Est. Completion 2030-02
Phase NA

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT06269510

The ClinicalTrials.gov registry entry for NCT06269510 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61,150-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Liver Diseases appearing as the primary indexed condition, and to 3 interventions - of which Enhanced Usual Care is the first listed.

NCT06269510 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT06269510 about?

NCT06269510 is a clinical study titled "Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients". The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.

What is the current status of trial NCT06269510?

This trial is currently recruiting. It is a NA study. The enrollment target is 268 participants. The study started on 2026-01-28. Estimated completion is 2030-02.

What conditions does trial NCT06269510 study?

This clinical trial studies the following conditions: Liver Diseases, Alcohol-related Liver Disease.

What interventions are being tested in trial NCT06269510?

The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), ENGAGE-ALD Application (APP) (BEHAVIORAL), Treatment Facilitation bundle (BEHAVIORAL).

Who is sponsoring clinical trial NCT06269510?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06269510 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Liver Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.